Table 1.
Baseline characteristics of the 149 patients.
| Characteristic | N (%) |
|---|---|
| Patients (n) | 149 |
| Age (median) | 70 (44–76) |
| Clinical stage | |
| T1a | 1 (0.6%) |
| T1b | 1 (0.6%) |
| T1c | 90 (60.4%) |
| T2a | 30 (20.1%) |
| T2b | 15 (10%) |
| T2c | 6 (4%) |
| T3a | 6 (4%) |
| Baseline Gleason score | |
| 2–6 | 76 (51%) |
| 7 | 51 (34%) |
| 8–10 | 22 (15%) |
| Initial PSA level (ng/mL) | |
| Mean | 18.6 |
| Range | 3.2–115 |
| Risk stratification | |
| Low risk | 51 (34.2%) |
| Intermediate risk | 55 (36.9%) |
| High risk | 43 (28.8%) |
| Androgen treatment | 98 (65.7%) |
| Comorbidities (hypertension or diabetes) | 58 (39%) |
| Follow-up (mo) | 53 (24–62) |